Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CERo Therapeutics Hldgs Q3 EPS $(9.10) Misses $(2.94) Estimate

Author: Benzinga Newsdesk | November 19, 2025 07:36pm
CERo Therapeutics Hldgs (NASDAQ:CERO) reported quarterly losses of $(9.10) per share which missed the analyst consensus estimate of $(2.94) by 210.05 percent. This is a 94.65 percent increase over losses of $(170.22) per share from the same period last year.

Posted In: CERO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist